Wellington Biomedical Innovation Master Investors (Cayman) II L.P. 4
4 · MBX Biosciences, Inc. · Filed Sep 17, 2024
Insider Transaction Report
Form 4
Transactions
- Conversion
Common Stock
2024-09-16+403,787→ 1,790,122 total - Conversion
Series B Preferred Stock
2024-09-16−16,666,666→ 0 total→ Common Stock (1,386,335 underlying) - Conversion
Common Stock
2024-09-16+1,386,335→ 1,386,335 total - Conversion
Series C Preferred Stock
2024-09-16−4,854,368→ 0 total→ Common Stock (403,787 underlying)
Footnotes (2)
- [F1]Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 12.0221-for-one basis. The Series B Preferred Stock had no expiration date.
- [F2]Immediately prior to the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 12.0221-for-one basis. The Series C Preferred Stock had no expiration date.